Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Europe Finance Weekly.
Press releases published on March 2, 2025

Acki Nacki Secures Over $6M in Preparation For Network Launch
SOFIA, Bulgaria, March 02, 2025 (GLOBE NEWSWIRE) -- GOSH, the core developer behind Acki Nacki, has announced today the successful completion of its pre-launch Node Sale, securing backing from validators including Kingsway Capital, Blockchain.com, Hack VC, …

CREEPZ Emerges from Stealth, Announces Flagship Games, Retail Drops & Major Partnerships
LOS ANGELES, March 02, 2025 (GLOBE NEWSWIRE) -- After operating under the radar, CREEPZ is officially emerging from stealth, transforming from a $400M+ NFT phenomenon into a full-scale entertainment brand. Backed by WME, major esports organizations, and …

Bybit Web3 Pioneers AI Agent Acceleration: Launches First AI-DOL Reality Competition with $1M Prize
DUBAI, United Arab Emirates, March 02, 2025 (GLOBE NEWSWIRE) -- Bybit Web3, the Web3 division of Bybit, is thrilled to accelerate AI innovation with the launch of its first AI-focused accelerator program - AI-DOL SUPERSTAR: Battle for Debut. This …

CGTN: How did China lay a good foundation for 2025 economic development
BEIJING, March 02, 2025 (GLOBE NEWSWIRE) -- CGTN publishes an article detailing how China prepared itself for economic growth in 2025 through a combination of targeted stimulus measures and high-level policy frameworks. China's economy has shown a …

TransPerfect Acquires Technicolor Games
SAN FRANCISCO and BANGALORE, India, March 01, 2025 (GLOBE NEWSWIRE) -- TransPerfect, the world’s largest provider of language and AI solutions for global business, today announced it has acquired Technicolor Games, the gaming division of Technicolor Group, …

Merus gibt Finanzergebnisse für das vierte Quartal und das Gesamtjahr 2024 bekannt und berichtet über die Geschäftsentwicklung
- Phase-III-Zulassungsstudien zu Petosemtamab in Kombination mit Pembrolizumab in der Erstlinienbehandlung des PD-L1-positiven rezidivierten/metastasierten Kopf-Hals-Plattenepithelkarzinoms (r/m HNSCC) und Petosemtamab als Monotherapie in der Zweit-/ …

Merus annonce les résultats financiers de son quatrième trimestre et de l’ensemble de son exercice 2024, et fait le point sur ses activités
- Inclusion en cours pour les études d’enregistrement de phase III visant l’évaluation du pétosemtamab en association avec le pembrolizumab en traitement de 1ᵉ ligne pour un CETC r/m PD-L1 et l’évaluation du pétosemtamab en monothérapie de 2ᵉ et 3ᵉ ligne …